Nuo Therapeutics, Inc. (AURX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 700K 1.4M 2.1M Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 38.2K Q4 '22: 74K Q1 '23: 61.1K Q2 '23: 118.2K Q3 '23: 232.2K Q4 '23: 197K Q1 '24: 234.6K Q2 '24: 364.8K Q3 '24: 371K Q4 '24: 394.9K Q1 '25: 484.4K Q2 '25: 700.2K Q3 '25: 1M Q4 '25: 1.1M Q1 '26: 1.3M Q2 '26: 1.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 400K 800K 1.2M Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 31.8K Q4 '22: 61.3K Q1 '23: 50.7K Q2 '23: 97.7K Q3 '23: 178.4K Q4 '23: 155.6K Q1 '24: 184K Q2 '24: 299.4K Q3 '24: 270.4K Q4 '24: 308.5K Q1 '25: 363.4K Q2 '25: 540.9K Q3 '25: 625.4K Q4 '25: 688.4K Q1 '26: 849.7K Q2 '26: 1.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q3 '21: -6.8K Q4 '21: -71.7K Q1 '22: -521.8K Q2 '22: -923.7K Q3 '22: -911.9K Q4 '22: -963.2K Q1 '23: -855.2K Q2 '23: -871.4K Q3 '23: -789.6K Q4 '23: -652.1K Q1 '24: -709.2K Q2 '24: -542K Q3 '24: -577.4K Q4 '24: -629.2K Q1 '25: -745.1K Q2 '25: -652K Q3 '25: -540.1K Q4 '25: -579.3K Q1 '26: -446.5K Q2 '26: -166.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q3 '21: -6.8K Q4 '21: -71.7K Q1 '22: -375.4K Q2 '22: -924K Q3 '22: -912.8K Q4 '22: -959.5K Q1 '23: -855.8K Q2 '23: -871.9K Q3 '23: -790.6K Q4 '23: -653.2K Q1 '24: -708.8K Q2 '24: -540.1K Q3 '24: -578.2K Q4 '24: -496.7K Q1 '25: -746.1K Q2 '25: -649.7K Q3 '25: -537.9K Q4 '25: -578.5K Q1 '26: -618.5K Q2 '26: -277.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 250K 500K 750K Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 6.5K Q4 '22: 12.7K Q1 '23: 10.4K Q2 '23: 20.5K Q3 '23: 53.8K Q4 '23: 41.4K Q1 '24: 50.6K Q2 '24: 65.3K Q3 '24: 100.5K Q4 '24: 86.4K Q1 '25: 121K Q2 '25: 159.3K Q3 '25: 406.7K Q4 '25: 408.5K Q1 '26: 452.4K Q2 '26: 599K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q3 '21: -3.2K Q4 '21: -107K Q1 '22: -737.3K Q2 '22: -1.1M Q3 '22: -1M Q4 '22: -821.7K Q1 '23: -795.6K Q2 '23: -905.9K Q3 '23: -794.9K Q4 '23: -671.4K Q1 '24: -562.4K Q2 '24: -691.2K Q3 '24: -487.5K Q4 '24: -490.5K Q1 '25: 1.8K Q2 '25: 262.4K Q3 '25: -706.5K Q4 '25: -422.6K Q1 '26: -784.3K Q2 '26: -236.5K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-1.5M -1M -500K 0 500K 1M 1.5M Q3 '21: -3.2K Q4 '21: -107K Q1 '22: -749.2K Q2 '22: -1.2M Q3 '22: -1M Q4 '22: -826.3K Q1 '23: -800.9K Q2 '23: -905.9K Q3 '23: -796.8K Q4 '23: -671.4K Q1 '24: -562.4K Q2 '24: -695.3K Q3 '24: -638.3K Q4 '24: -490.5K Q1 '25: -228.1K Q2 '25: 260.7K Q3 '25: -706.5K Q4 '25: -465.9K Q1 '26: -785.1K Q2 '26: -489.5K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 30.5M Q2 '20: 24.2M Q3 '20: 24.2M Q1 '21: 30.3M Q2 '21: 30.3M Q3 '21: 30.3M Q1 '22: 37.1M Q2 '22: 39.8M Q3 '22: 41.1M Q1 '23: 41.8M Q2 '23: 41.8M Q3 '23: 42.1M Q1 '24: 44.2M Q2 '24: 44.7M Q3 '24: 45.6M Q1 '25: 46.8M Q2 '25: 46.8M Q3 '25: 47.5M Q1 '26: 48.3M Q2 '26: 48.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.10 0.00 0.10 0.20 0.30 Q3 '21: 0.28 Q4 '21: -0.03 Q1 '22: -0.04 Q2 '22: -0.06 Q3 '22: -0.08 Q4 '22: -0.07 Q1 '23: -0.08 Q2 '23: -0.08 Q3 '23: -0.08 Q4 '23: -0.08 Q1 '24: -0.08 Q2 '24: -0.07 Q3 '24: -0.06 Q4 '24: -0.05 Q1 '25: -0.05 Q2 '25: -0.05 Q3 '25: -0.05 Q4 '25: -0.05 Q1 '26: -0.04 Q2 '26: -0.04 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.